Partnership Highlights*
Our licensing efforts with others invested in eye health have led to several notable partnerships. We are honored to have the chance to produce such results with these other prestigious organizations.
Alcon Recent Partnerships and Acquisitions
 |
Five-year collaborative research for the exclusive ophthalmic discovery and potential development agreement rights to AstraZeneca’s compound library |
 |
Acquisition of Swiss Biotechnology Firm, ESBATech AG, giving access to proprietary antibody fragment technology particularly suited to treat eye diseases |
 |
Acquisition of LenSx Lasers, Inc., developer of femtosecond laser technology for increased precision of manual surgical steps during cataract surgery |
 |
Acquisition of Optonol, Ltd., a medical device company that develops, manufactures and markets Ex-PRESS® mini glaucoma shunt, a surgical implant used to lower intraocular pressure in patients with glaucoma |
|
|
License to develop Potentia’s leading drug candidate, POT-4, for the treatment of age-related macular degeneration (AMD) |
* All trademarks are properties of their respective owners.
Back to top
